Uniphar PLC has acquired BModesto Vastgoed B.V.
Irish-listed healthcare group Uniphar PLC has acquired Dutch pharmaceutical services business BModesto Group. The acquisition strengthens Uniphar’s product access offering in Europe.
Uniphar is a global partner to pharmaceutical and medtech manufacturers working to improve patient access to medicines in Europe and around the world. It provides outsourced and specialized services to its clients and leverages strong relationships with over 200 of the world’s best-known pharmaco-medical manufacturers in multiple geographies. Uniphar operates across three core divisions: pharmaceuticals—a global business providing on-demand and medicine-sourcing solutions along with outsourced specialist services to pharmaceutical manufacturers; medtech—a leading European medical device distributor with a presence in 21 markets; and supply chain and retail—a market leader in Ireland with around 50% of the wholesale market and four nationwide pharmacy symbol groups. Uniphar is listed on the LSE and Euronext Dublin.
BModesto is a healthcare services business focused on improving access to pharmaceutical and healthcare products across the Netherlands, Germany, the UK and Europe. The company services include the distribution of medicines on both an exclusive and on-demand basis. It has a workforce of more than 180 people, and since its foundation in 2014, it has built up a strong international sourcing network to gain access to these much needed and often difficult-to-source medicines.
Oaklins’ team in Ireland acted as the exclusive buy-side M&A advisor to Uniphar and assisted in all aspects, from initiating the transaction to structuring and negotiating premium deal terms. This deal complements a long list of acquisitions the team has advised on for Uniphar.
Talk to the deal team
Related deals
Medicija has acquired Saulės Šeimos Medicinos Centras
Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.
Learn moreQuimpharma has completed the divestiture of a product portfolio to Megalabs
Quimpharma has completed the divestiture of a product portfolio to Megalabs México.
Learn moreIXICO has completed a fundraising
IXICO plc, a specialist in AI-driven neuroimaging analytics, has completed a US$13.5 million gross capital raise. The funds will be used to support the company’s tech bio strategy, which will see IXICO partner its platform to maximize its potential.
Learn more